

Sarah A Milgrom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7199162/publications.pdf>

Version: 2024-02-01

86
papers

1,328
citations

393982

19
h-index

414034

32
g-index

87
all docs

87
docs citations

87
times ranked

1823
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Therapy for Young Children Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Brain Tumors. <i>Advances in Radiation Oncology</i> , 2022, , 100945.	0.6	1
2	RONC-05. Peri-transplant Radiation Therapy for Young Children Treated with High-Dose Chemotherapy for Primary Brain Tumors. <i>Neuro-Oncology</i> , 2022, 24, i177-i177.	0.6	0
3	Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 479-488.	0.4	5
4	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	0.6	4
5	Improving the Pediatric Patient Experience During Radiation Therapy-A Children's Oncology Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 505-514.	0.4	11
6	Medical and rehabilitation interventions in pediatric central nervous system radiation necrosis: A case report. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28705.	0.8	0
7	Non-rhabdomyosarcoma soft-tissue sarcoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28279.	0.8	9
8	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
9	Salivary and Dental Complications in Childhood Cancer Survivors Treated With Radiation Therapy to the Head and Neck: A Pediatric Normal Tissue Effects in the Clinic (PENTEC) Comprehensive Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	12
10	Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29212.	0.8	13
11	Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> . 2021, 111, 907-916.	0.4	8
12	The optimal use of PET/CT in the management of lymphoma patients. <i>British Journal of Radiology</i> , 2021, 94, 20210470.	1.0	8
13	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. <i>Redox Biology</i> , 2021, 47, 102132.	3.9	17
14	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.4	6
15	Secondary central nervous system diffuse large cell lymphoma: an opportunity for radiation therapy to improve outcomes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-4.	0.6	5
16	Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1554-1562.	0.6	2
17	Brachytherapy in children, adolescents, and young adults: An underutilized modality in the United States?. <i>Pediatric Blood and Cancer</i> , 2021, , e29412.	0.8	2
18	Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 841-850.	0.4	10

#	ARTICLE	IF	CITATIONS
19	SMILE and Beam On. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1105.	0.4	1
20	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leukemia and Lymphoma, 2020, 61, 171-175.	0.6	14
21	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. Advances in Radiation Oncology, 2020, 5, 1255-1266.	0.6	11
22	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Network Open, 2020, 3, e2013935.	2.8	8
23	Integration of automation into an existing clinical workflow to improve efficiency and reduce errors in the manual treatment planning process for total body irradiation (TBI). Journal of Applied Clinical Medical Physics, 2020, 21, 100-106.	0.8	4
24	Association or Causality: Does Whole Brain Proton Radiotherapy Not Impact IQ?. Journal of Clinical Oncology, 2020, 38, 2211-2212.	0.8	2
25	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Advances, 2020, 4, 2064-2072.	2.5	6
26	Striking a Delicate Balance: Disease Control Without Neurotoxicity. International Journal of Radiation Oncology Biology Physics, 2020, 107, 401.	0.4	0
27	The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 398-400.	0.4	5
28	Stage III nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	0.6	30
29	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica, 2020, 105, e355-e357.	1.7	10
30	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 533-541.	0.2	2
31	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leukemia and Lymphoma, 2019, 60, 3258-3265.	0.6	1
32	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiotherapy and Oncology, 2019, 131, 88-92.	0.3	6
33	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e465-e469.	0.2	7
34	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2019, 104, 501-512.	0.4	30
35	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. Practical Radiation Oncology, 2019, 9, 147-152.	1.1	0
36	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 447-455.	0.4	31

#	ARTICLE	IF	CITATIONS
37	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 381-389.	0.2	3
38	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 2432-2440.	0.6	2
39	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 244-250.	0.2	11
40	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. <i>Scientific Reports</i> , 2019, 9, 1322.	1.6	62
41	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12
42	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
43	Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. <i>British Journal of Haematology</i> , 2019, 184, 292-293.	1.2	0
44	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 268.	0.2	30
45	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
46	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
47	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 2650-2659.	0.6	2
48	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1100-1118.	0.4	46
49	Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 545-549.	1.2	38
50	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. <i>Leukemia and Lymphoma</i> , 2018, 59, 2896-2903.	0.6	12
51	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 530-540.	0.4	23
52	Deep-Inspiration Breath-Hold Intensity Modulated Radiation Therapy to the Mediastinum for Lymphoma Patients: Setup Uncertainties and Margins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 254-262.	0.4	13
53	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. <i>Blood</i> , 2018, 131, 84-94.	0.6	78
54	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8937-8942.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	2.5	23
56	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. <i>Case Reports in Oncology</i> , 2018, 11, 721-728.	0.3	1
57	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	0.6	9
58	Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. <i>Advances in Radiation Oncology</i> , 2018, 3, 372-381.	0.6	6
59	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2833-2844.	0.6	13
60	The Management of Lymphoma in the Setting of Pregnancy. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 251-256.	1.2	29
61	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 363-369.	0.6	9
62	Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. <i>Head and Neck</i> , 2017, 39, 1095-1100.	0.9	87
63	Daily CT guidance improves target coverage during definitive radiation therapy for gastric MALT lymphoma. <i>Practical Radiation Oncology</i> , 2017, 7, e471-e478.	1.1	13
64	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57
65	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. <i>Radiotherapy and Oncology</i> , 2017, 122, 66-71.	0.3	76
66	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 1363-1371.	2.0	18
67	Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. <i>British Journal of Haematology</i> , 2017, 179, 488-496.	1.2	9
68	Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. <i>Advances in Radiation Oncology</i> , 2017, 2, 370-380.	0.6	5
69	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. <i>Practical Radiation Oncology</i> , 2017, 7, e401-e408.	1.1	21
70	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 333-338.	0.4	10
71	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160.	2.0	30
72	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. <i>Journal of Medical Case Reports</i> , 2016, 10, 209.	0.4	2

#	ARTICLE	IF	CITATIONS
73	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	2.0	15
74	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 110-118.	0.4	9
75	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2612-2618.	0.6	1
76	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 951-958.	0.4	6
77	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. <i>JAMA Oncology</i> , 2016, 2, 1065.	3.4	36
78	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
79	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , 2016, 18, 575-581.	0.6	24
80	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 34-38.	0.6	34
81	Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. <i>Radiation Oncology</i> , 2015, 10, 206.	1.2	1
82	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 175-182.	0.4	110
83	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 664-670.e2.	0.2	4
84	Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. <i>Blood</i> , 2015, 126, 1980-1980.	0.6	1
85	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , 2015, 126, 3865-3865.	0.6	0
86	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. <i>Blood</i> , 2015, 126, 1511-1511.	0.6	0